Ribi, Karin, Luo, Weixiu, Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Colleoni, Marco, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L.. Nature Publishing Group; 2019. Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Crivellari, Diana, Sun, Zhuoxin, Gelber, Richard D., Colleoni, Marco, Lang, Istvan, Del Mastro, Lucia, Gladieff, Laurence, Rabaglio, Manuela, Smith, Ian E., Chirgwin, Jacquie H., Goldhirsch, Aron, Coates, Alan S., Price, Karen N., Thurlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert J., Castiglione-Gertsch, Monica. American Society of Clinical Oncology; 2008. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

Ewertz, Marianne, Gray, Kathryn P., Gelber, Richard D., Colleoni, Marco, Láng, István, Smith, Ian E., Coates, Alan S., Goldhirsch, Aron, Mouridsen, Henning T., Regan, Meredith M., Ejlertsen, Bent, Price, Karen N., Thürlimann, Beat, Bonnefoi, Hervé, Forbes, John F., Paridaens, Robert J., Rabaglio, Manuela. American Society of Clinical Oncology; 2012. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial.

Regan, Meredith M., Neven, Patrick, Rabaglio, Manuela, Price, Karen N., Gelber, Richard D., Coates, Alan S., Thürlimann, Beat, Giobbie-Hurder, Anita, Goldhirsch, Aron, Ejlertsen, Bent, Mauriac, Louis, Forbes, John F., Smith, Ian, Láng, István, Wardley, Andrew. Elsevier; 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up.

Chirgwin, Jacquie H., Giobbie-Hurder, Anita, Forbes, John F., Neven, Patrick, Láng, István, Colleoni, Marco, Thürlimann, Beat, Coates, Alan S., Price, Karen N., Ejlertsen, Bent, Debled, Marc, Gelber, Richard D., Goldhirsch, Aron, Smith, Ian, Rabaglio, Manuela. American Society of Clinical Oncology; 2016. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence.

Johansson, Harriet, Gray, Kathryn P., Colleoni, Marco, Rabaglio, Manuela, Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A., TEXT principal investigators,, Pagani, Olivia, Chirgwin, Jaqueline, Francis, Prudence, Regan, Meredith M., Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf. BioMed Central; 2016. Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.

Regan, Meredith M., Pagani, Olivia, Colleoni, Marco, Gelber, Richard D., Francis, Prudence A., International Breast Cancer Study Group (IBCSG),, SOFT Investigators,, TEXT Investigators,, Fleming, Gini F., Walley, Barbara A., Price, Karen N., Rabaglio, Manuela, Maibach, Rudolf, Ruepp, Barbara, Coates, Alan S., Goldhirsch, Aron. Elsevier; 2013. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.